BidaskClub downgraded shares of ABIOMED (NASDAQ:ABMD) from a strong-buy rating to a buy rating in a report released on Tuesday, BidAskClub reports.

Several other equities analysts have also recently issued reports on ABMD. OTR Global raised ABIOMED to a positive rating in a report on Monday, July 13th. Morgan Stanley boosted their price target on ABIOMED from $152.00 to $217.00 and gave the stock an underweight rating in a report on Friday, August 7th. SVB Leerink boosted their price target on ABIOMED from $280.00 to $335.00 and gave the stock a market perform rating in a report on Friday, August 7th. Finally, BTIG Research cut ABIOMED to a hold rating in a report on Wednesday, May 27th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $221.40.

Shares of ABMD stock opened at $302.34 on Tuesday. The stock has a fifty day moving average price of $280.11 and a 200 day moving average price of $206.13. The stock has a market cap of $13.52 billion, a PE ratio of 87.13, a P/E/G ratio of 4.15 and a beta of 0.99. ABIOMED has a 1 year low of $119.01 and a 1 year high of $319.19.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.38. The firm had revenue of $164.90 million during the quarter, compared to analysts’ expectations of $144.12 million. ABIOMED had a return on equity of 16.17% and a net margin of 19.88%. ABIOMED’s revenue was down 20.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.00 earnings per share. As a group, sell-side analysts anticipate that ABIOMED will post 3.71 EPS for the current year.

In other news, Director Paul Thomas sold 2,000 shares of ABIOMED stock in a transaction on Monday, August 10th. The stock was sold at an average price of $303.41, for a total value of $606,820.00. Also, Director Dorothy E. Puhy sold 7,500 shares of ABIOMED stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $275.00, for a total value of $2,062,500.00. Following the completion of the sale, the director now directly owns 7,652 shares of the company’s stock, valued at approximately $2,104,300. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in ABMD. FMR LLC grew its position in ABIOMED by 287.2% during the first quarter. FMR LLC now owns 30,927 shares of the medical equipment provider’s stock valued at $8,833,000 after acquiring an additional 22,940 shares during the period. State of Alaska Department of Revenue grew its position in ABIOMED by 4.6% during the first quarter. State of Alaska Department of Revenue now owns 7,768 shares of the medical equipment provider’s stock valued at $1,127,000 after acquiring an additional 345 shares during the period. Capital Investment Advisors LLC grew its position in ABIOMED by 5.9% during the first quarter. Capital Investment Advisors LLC now owns 3,984 shares of the medical equipment provider’s stock valued at $578,000 after acquiring an additional 222 shares during the period. Central Bank & Trust Co. purchased a new stake in ABIOMED during the first quarter valued at about $1,650,000. Finally, Brookstone Capital Management grew its position in ABIOMED by 5.2% during the first quarter. Brookstone Capital Management now owns 2,642 shares of the medical equipment provider’s stock valued at $384,000 after acquiring an additional 131 shares during the period. 94.43% of the stock is owned by institutional investors and hedge funds.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: Catch-Up Contributions

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.